vs
Side-by-side financial comparison of Azenta, Inc. (AZTA) and Esperion Therapeutics, Inc. (ESPR). Click either name above to swap in a different company.
Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $148.6M, roughly 1.1× Azenta, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 0.8%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs 4.4%).
Azenta, was founded in 1978, and is based in Chelmsford, Massachusetts, United States. The company is a provider of life sciences services including genomics, cryogenic storage, automation, and informatics.
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
AZTA vs ESPR — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $148.6M | $168.4M |
| Net Profit | $-15.4M | — |
| Gross Margin | 42.9% | — |
| Operating Margin | -4.9% | 50.6% |
| Net Margin | -10.4% | — |
| Revenue YoY | 0.8% | 143.7% |
| Net Profit YoY | -15.7% | — |
| EPS (diluted) | $-0.34 | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $148.6M | $168.4M | ||
| Q3 25 | $159.2M | $87.3M | ||
| Q2 25 | $143.9M | $82.4M | ||
| Q1 25 | $143.3M | $65.0M | ||
| Q4 24 | $147.4M | $69.1M | ||
| Q3 24 | $150.6M | $51.6M | ||
| Q2 24 | $144.3M | $73.8M | ||
| Q1 24 | $136.4M | $137.7M |
| Q4 25 | $-15.4M | — | ||
| Q3 25 | $50.9M | $-31.3M | ||
| Q2 25 | $-48.0M | $-12.7M | ||
| Q1 25 | $-47.7M | $-40.5M | ||
| Q4 24 | $-11.0M | — | ||
| Q3 24 | $-6.6M | $-29.5M | ||
| Q2 24 | $-6.6M | $-61.9M | ||
| Q1 24 | $-137.4M | $61.0M |
| Q4 25 | 42.9% | — | ||
| Q3 25 | 45.4% | — | ||
| Q2 25 | 46.2% | — | ||
| Q1 25 | 43.8% | — | ||
| Q4 24 | 46.7% | — | ||
| Q3 24 | 45.5% | — | ||
| Q2 24 | 44.8% | — | ||
| Q1 24 | 43.8% | — |
| Q4 25 | -4.9% | 50.6% | ||
| Q3 25 | 1.2% | -11.4% | ||
| Q2 25 | -1.3% | 8.6% | ||
| Q1 25 | -12.7% | -34.0% | ||
| Q4 24 | -5.9% | -6.4% | ||
| Q3 24 | -3.1% | -31.0% | ||
| Q2 24 | -4.9% | 3.5% | ||
| Q1 24 | -18.1% | 52.5% |
| Q4 25 | -10.4% | — | ||
| Q3 25 | 32.0% | -35.9% | ||
| Q2 25 | -33.4% | -15.4% | ||
| Q1 25 | -33.3% | -62.2% | ||
| Q4 24 | -7.5% | — | ||
| Q3 24 | -4.4% | -57.2% | ||
| Q2 24 | -4.5% | -83.9% | ||
| Q1 24 | -100.8% | 44.3% |
| Q4 25 | $-0.34 | $0.32 | ||
| Q3 25 | $1.12 | $-0.16 | ||
| Q2 25 | $-1.05 | $-0.06 | ||
| Q1 25 | $-1.04 | $-0.21 | ||
| Q4 24 | $-0.25 | $-0.14 | ||
| Q3 24 | $-0.25 | $-0.15 | ||
| Q2 24 | $-0.12 | $-0.33 | ||
| Q1 24 | $-2.48 | $0.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $336.6M | $167.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.7B | $-302.0M |
| Total Assets | $2.1B | $465.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $336.6M | $167.9M | ||
| Q3 25 | $279.8M | $92.4M | ||
| Q2 25 | $270.0M | $86.1M | ||
| Q1 25 | $253.6M | $114.6M | ||
| Q4 24 | $377.5M | $144.8M | ||
| Q3 24 | $280.0M | $144.7M | ||
| Q2 24 | $336.5M | $189.3M | ||
| Q1 24 | $353.5M | $226.6M |
| Q4 25 | $1.7B | $-302.0M | ||
| Q3 25 | $1.7B | $-451.4M | ||
| Q2 25 | $1.7B | $-433.5M | ||
| Q1 25 | $1.7B | $-426.2M | ||
| Q4 24 | $1.7B | $-388.7M | ||
| Q3 24 | $1.8B | $-370.2M | ||
| Q2 24 | $2.0B | $-344.2M | ||
| Q1 24 | $2.2B | $-294.3M |
| Q4 25 | $2.1B | $465.9M | ||
| Q3 25 | $2.1B | $364.0M | ||
| Q2 25 | $2.0B | $347.1M | ||
| Q1 25 | $2.0B | $324.0M | ||
| Q4 24 | $2.0B | $343.8M | ||
| Q3 24 | $2.1B | $314.1M | ||
| Q2 24 | $2.3B | $352.3M | ||
| Q1 24 | $2.6B | $373.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $20.8M | $45.2M |
| Free Cash FlowOCF − Capex | $14.7M | — |
| FCF MarginFCF / Revenue | 9.9% | — |
| Capex IntensityCapex / Revenue | 4.2% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $30.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $20.8M | $45.2M | ||
| Q3 25 | $2.2M | $-4.3M | ||
| Q2 25 | $25.8M | $-31.4M | ||
| Q1 25 | $14.4M | $-22.6M | ||
| Q4 24 | $29.8M | $-35.0M | ||
| Q3 24 | $17.7M | $-35.3M | ||
| Q2 24 | $9.8M | $-7.2M | ||
| Q1 24 | $8.7M | $53.8M |
| Q4 25 | $14.7M | — | ||
| Q3 25 | $-5.7M | — | ||
| Q2 25 | $15.0M | — | ||
| Q1 25 | $7.0M | — | ||
| Q4 24 | $22.0M | — | ||
| Q3 24 | $8.3M | $-35.5M | ||
| Q2 24 | $1.3M | $-7.3M | ||
| Q1 24 | $428.0K | $53.8M |
| Q4 25 | 9.9% | — | ||
| Q3 25 | -3.6% | — | ||
| Q2 25 | 10.4% | — | ||
| Q1 25 | 4.9% | — | ||
| Q4 24 | 15.0% | — | ||
| Q3 24 | 5.5% | -68.7% | ||
| Q2 24 | 0.9% | -9.9% | ||
| Q1 24 | 0.3% | 39.0% |
| Q4 25 | 4.2% | 0.0% | ||
| Q3 25 | 4.9% | 0.0% | ||
| Q2 25 | 7.5% | 0.0% | ||
| Q1 25 | 5.2% | 0.0% | ||
| Q4 24 | 5.3% | 0.0% | ||
| Q3 24 | 6.2% | 0.3% | ||
| Q2 24 | 5.9% | 0.1% | ||
| Q1 24 | 6.1% | 0.1% |
| Q4 25 | — | — | ||
| Q3 25 | 0.04× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.88× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AZTA
| Multiomics | $67.2M | 45% |
| Core Products | $47.6M | 32% |
| Sample Repository Solutions | $33.8M | 23% |
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
